ECE1

Endothelin-converting enzyme 1 · P42892 · ECE1 on Sugi Atlas →

39,267 patent compounds predicted against ECE1, 25,212 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL489801	0.73	13/20
Valyltryptophan (SCHEMBL150532)	0.72	12/20
Valyltryptophan (SCHEMBL150533)	0.72	12/20
SCHEMBL653010	0.67	10/20
SCHEMBL653011	0.67	10/20
SCHEMBL852503	0.57	8/20
Phosphoramidon (SCHEMBL40933)	1.00	6/20
Phosphoramidon (SCHEMBL117398)	1.00	6/20
Acetyltryptophan (SCHEMBL57140)	0.67	6/20
Acetyltryptophan (SCHEMBL57141)	0.67	6/20
Acetyltryptophan (SCHEMBL702442)	0.67	6/20
SCHEMBL57729	0.54	6/20
SCHEMBL642928	0.54	6/20
SCHEMBL56605	0.53	6/20
SCHEMBL187794	0.46	6/20
SCHEMBL170877	0.65	5/20
SCHEMBL170878	0.65	5/20
Tryptophan (SCHEMBL531051)	0.58	5/20
SCHEMBL200969	0.57	5/20
SCHEMBL126762	0.55	5/20

Clinical trials — most relevant to ECE1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Direct Renin Inhibition Effects on Atherosclerotic Biomarkers	PHASE4	COMPLETED
Bosentan in Treatment of Pulmonary Arterial Hypertension	PHASE4	COMPLETED
Inhaled Iloprost for Disproportionate Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease (COPD)	PHASE4	UNKNOWN
Impact of Estradiol on Endothelial Function in Peri-Menopausal Women	PHASE4	ACTIVE_NOT_RECRUITING
Correlation of Endothelial Function and Early Coronary Artery Disease in Humans	PHASE3	COMPLETED
Safety and Efficacy of Bosentan in Patients With Diastolic Heart Failure and Secondary Pulmonary Hypertension	PHASE3	COMPLETED
Treatment of Severe COVID-19 Pneumonia With Allogeneic Mesenchymal Stem Cells	PHASE2	COMPLETED
Dapagliflozin and Endothelin Receptor Antagonism in Large Vessel Vasculitis (DERAIL-LVV)	PHASE2	RECRUITING
L-citrulline Supplementation & Cold Exposure	PHASE1/PHASE2	COMPLETED
ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC)	PHASE2	ACTIVE_NOT_RECRUITING
Endothelin-Receptor Blockade in Coronary Heart Disease	PHASE1	COMPLETED
Inter-individual Physiological Response to a Training and Detraining Period in Cardiometabolic Risk Factors Subjects	nan	COMPLETED
Endothelial Effects of VEGF Inhibition In Vivo in Man	nan	COMPLETED
Proteolytic Enzyme Induction Within the Human Myocardial Interstitium	nan	COMPLETED
Role of Endothelin in the Regulation of Vascular Tone in Patients With Essential Hypertension	nan	COMPLETED
Role of Endothelin-1 in Flow-mediated Dilatation	nan	COMPLETED
Racial Differences: Nitric Oxide(NO) and Endothelin-1(ET-1) in Preeclampsia (PreE)	nan	COMPLETED
Antecedents of Hypertension: Role of Race and Stress	nan	COMPLETED
Blood Flow Responses to an Oral Glucose Tolerance Test in Type 2 Diabetes	nan	COMPLETED
Study of the Interaction Between the Cells Lining Blood Vessels and Angiotensin-Converting Enzyme	nan	COMPLETED
Effects of Rosiglitazone on Blood Vessels in Patients With High Blood Pressure and High Cholesterol	nan	COMPLETED
Serum Vasohibin, Cardiotrophin, Endocan & Perinatal Outcomes	nan	UNKNOWN
Endothelin Role In COronary Microcirculation	nan	ACTIVE_NOT_RECRUITING
Endothelial Dysfunction in Covid-19	nan	UNKNOWN
Angiotensin Converting Enzyme (ACE) Inhibition and Cardiac Allograft Vasculopathy	nan	COMPLETED
Efficacy and Safety of Angiotensin II Use in Coronavirus Disease(COVID)-19 Patients With Acute Respiratory Distress Syndrome	nan	UNKNOWN
Lung Injury (Pulmonary Edema) in COVID-19: Treatment With Furosemide and Negative Fluid Balance (NEGBAL)	nan	COMPLETED
The Contribution of Endothelin to Vasomotor Function in Diseased Coronary Arteries	nan	COMPLETED
The Impact of ERA Switching on Risk Stratification in Pulmonary Arterial Hypertension	nan	RECRUITING
Effect of Propionic Acid Supplementation on Endothelial Function	nan	NOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a ECE1 binder may also engage these)

Protein	Name	Similarity
Q4PZA2	—	1.000	Q4PZA2 →
P42893	—	1.000	P42893 →
P42891	—	1.000	P42891 →
P97739	—	1.000	P97739 →
B2RQR8	—	1.000	B2RQR8 →
Q9JLI3	—	0.999	Q9JLI3 →
F1N476	—	0.999	F1N476 →
Q8IS64	—	0.998	Q8IS64 →
A0A0B4K692	—	0.997	A0A0B4K692 →
Q61391	—	0.995	Q61391 →
Q5RE69	—	0.995	Q5RE69 →
P0DPE2	—	0.995	P0DPE2 →
ECE2	Endothelin-converting enzyme 2	0.994	landscape →
O16796	—	0.994	O16796 →
P07861	—	0.994	P07861 →
MMEL1	Membrane metallo-endopeptidase-like 1	0.993	landscape →
Q18673	—	0.993	Q18673 →
P0C1T0	—	0.992	P0C1T0 →
MME	Neprilysin	0.992	landscape →
O95672	—	0.992	O95672 →
Q9JHL3	—	0.991	Q9JHL3 →
P0DPD9	—	0.991	P0DPD9 →
W4VS99	—	0.991	W4VS99 →
P08049	—	0.990	P08049 →
Q9W5Y0	—	0.990	Q9W5Y0 →
P0DPD8	—	0.990	P0DPD8 →
Q22523	—	0.989	Q22523 →
O44857	—	0.989	O44857 →
Q9JMI0	—	0.989	Q9JMI0 →
Q9W436	—	0.988	Q9W436 →